Show simple item record

dc.contributor.authorFarrar, Gwyneth
dc.date.accessioned2022-03-07T15:31:49Z
dc.date.available2022-03-07T15:31:49Z
dc.date.issued2021
dc.date.submitted2021en
dc.identifier.citationStephenson, K.A.J. and Zhu, J. and Wynne, N. and Dockery, A. and Cairns, R.M. and Duignan, E. and Whelan, L. and Malone, C.P. and Dempsey, H. and Collins, K. and Routledge, S. and Pandey, R. and Crossan, E. and Turner, J. and Oâ Byrne, J.J. and Brady, L. and Silvestri, G. and Kenna, P.F. and Farrar, G.J. and Keegan, D.J., Target 5000: a standardized all-Ireland pathway for the diagnosis and management of inherited retinal degenerations, Orphanet Journal of Rare Diseases, 2021, 16, 1en
dc.identifier.otherY
dc.identifier.urihttp://hdl.handle.net/2262/98250
dc.description.abstractIntroduction: Inherited retinal degenerations (IRD) are rare genetic disorders with > 300 known genetic loci, mani- festing variably progressive visual dysfunction. IRDs were historically underserved due to lack of effective interven- tions. Many novel therapies will require accurate diagnosis (phenotype and genotype), thus an efficient and effective pathway for assessment and management is required. Methods: Using surveys of existing practice patterns and advice from international experts, an all-Ireland IRD service (Target 5000) was designed. Detailed phenotyping was followed by next generation genetic sequencing in both a research and accredited laboratory. Unresolved pedigrees underwent further studies (whole gene/whole exome/ whole genome sequencing). Novel variants were interrogated for pathogenicity (cascade screening, in silico analysis, functional studies). A multidisciplinary team (MDT; ophthalmologists, physicians, geneticists, genetic counsellors) reconciled phenotype with genotype. A bespoke care plan was created for each patient comprising supports, existing interventions, and novel therapies/clinical trials. Results and discussion: Prior to Target 5000, a significant cohort of patients were not engaged with healthcare/sup- port services due to lack of effective interventions. Pathogenic or likely pathogenic variants in IRD-associated genes were detected in 62.3%, with 11.6% having variants of unknown significance. The genotyping arm of Target 5000 allowed a 42.73% cost saving over independent testing, plus the value of MDT expertise/processing. Partial funding has transferred from charitable sources to government resources. Conclusion: Target 5000 demonstrates efficacious and efficient clinical/genetic diagnosis, while discovering novel IRD-implicated genes/variants and investigating mechanisms of disease and avenues of intervention. This model could be used to develop similar IRD programmes in small/medium-sized nations.en
dc.language.isoenen
dc.relation.ispartofseriesOrphanet Journal of Rare Diseases;
dc.relation.ispartofseries16;
dc.relation.ispartofseries1;
dc.rightsYen
dc.subjectPublic and patient involvementen
dc.subjectClinical diagnostic algorithmen
dc.subjectInherited retinal degenerationsen
dc.subjectRetinal dystrophyen
dc.subjectOcular geneticsen
dc.subjectGenetic diagnosisen
dc.titleTarget 5000: a standardized all-Ireland pathway for the diagnosis and management of inherited retinal degenerationsen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/gjfarrar
dc.identifier.rssinternalid239067
dc.identifier.doihttp://dx.doi.org/10.1186/s13023-021-01841-1
dc.rights.ecaccessrightsopenAccess
dc.contributor.sponsorScience Foundation Ireland (SFI)en


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record